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ABSTRACT
Background and objective: Early diagnosis of chronic
obstructive pulmonary disease (COPD) in primary care
settings is difficult to achieve chiefly due to lack of
availability of spirometry. This study estimated the
prevalence of airflow limitation among chronic
smokers using a handheld spirometer in this setting.
Methods: This is a cross-sectional study performed
on consecutive patients who were ≥40 years old with
≥10 pack-years smoking history. Face-to-face inter-
viewswere carried out to obtain demographic data and
relevant information. Handheld spirometry was per-
formed according to a standard protocol using the
COPd-6 device (Model 4000, Vitalograph, Ennis,
Ireland) in addition to standard spirometry. Airflow
limitation was defined as ratio of forced expiratory
volume in 1 s (FEV1)/forced expiratory volume in 6 s
<0.75 (COPd-6) or FEV1/forced vital capacity <0.7.
Multiple logistic regression analyses were used to
determine predictors of airflow limitation.
Results: A total of 416 patients were recruited with
mean age of 53 years old. The prevalence of airflow
limitation was 10.6% (n = 44) with COPd-6 versus 6%
as gauged using standard spirometry. Risk factors for
airflow limitation were age >65 years (odds ratio (OR)
3.732 95% confidence interval (CI): 1.100–1.280), a
history of ‘bad health’ (OR 2.524, 95% CI: 1.037–6.142)
and low to normal body mass index (OR 2.914, 95% CI:
1.191–7.190).
Conclusions: In a primary care setting, handheld
spirometry (COPd-6) found a prevalence of airflow
limitation of ∼10% in smokers. Patients were older, not
overweight and had an ill-defined history of health
problems.
Key words: chronic obstructive pulmonary disease, Malaysia,
prevalence, primary care, smoke.
Abbreviations: BMI, body mass index; CI, confidence interval;
COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in first seconds; FEV6, forced expiratory
volume in first six seconds; FVC, forced vital capacity; IQR,
interquartile range; OR, odds ratio.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD), a
progressive partially reversible airflow obstructive
condition, is a growing public health problem glob-
ally. In its advanced stage, the disease causes severe
disabilities and poor quality of life.1–3 By 2030, it is
projected to be the third leading cause of deathworld-
wide with Asia, having three times the number of
patients than the rest of the world.4–6 Systematic
reviews have reported the prevalence of at least mod-
erately severe COPD among adult smokers, aged 40
years and above is in the range of 9.9–15.4%.7 Thus,
early detection of COPD is important to prevent the
continuous deterioration of lung function through
pharmacological intervention and more targeted
measures of smoking cessation.8–10
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SUMMARY AT A GLANCE
Prevalence of COPD is unknown in Malaysia. The
prevalence of COPD using a handheld spirometer
(COPd-6TM) was 10.6% versus 6% as gauged using
standard spirometry. Predictors of COPD were
older age, lower BMI and a history of ‘bad health’.
Case-finding for COPD should be targeted in this
special population.
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In primary care settings, early diagnosis of COPD is
a daunting task. Patients in the early stage of COPD
are relatively less symptomatic, thus tend not to high-
light their symptoms to health-care providers. By the
time the disease is brought to clinical attention, it is
usually in a more advanced stage, where the forced
expiratory volume in 1 s (FEV1) is typically below 50%
of predicted.11 Nevertheless, even if they do complain,
measurements of airflow limitation that are crucial
for the diagnosis are often not performed.12 Many of
the patients are misdiagnosed as having bronchial
asthma. General lack of availability and experience in
using spirometry among primary care physicians
contribute to this unfortunate circumstance.13
In recent years, handheld spirometers have been
made available by various manufacturers. These are
inexpensive, ultra-portable and easy to use. Thus,
these devices could be used as a case-finding tool for
COPD, particularly in primary care settings. Hand-
held spirometer has good sensitivity and specificity to
identify airflow limitation compared with standard
laboratory-based spirometry.14–19
However, few studies have used handheld devices
to detect the prevalence of airflow limitation in the
at-risk population in primary care, especially in a
developing country like Malaysia. Therefore, this
study aimed to determine prevalence and predictors
of airflow limitation in chronic smokers in a primary
care clinic.
METHODS
Study population
This cross-sectional study enrolled patients regis-
tered with the public primary health-care clinic at
the Sepang District in the state of Selangor in Malay-
sia from January to June 2012. The clinic is located in
a suburban area serving a predominantly Malay
population. All consecutive patients aged 40 years
and above who had smoking history of more than 10
pack-years, irrespective of whether a diagnosis of
COPD has been made previously, were recruited into
the study. Patients with recent active tuberculosis,
haemoptysis, pneumothorax and human immuno-
deficiency virus were excluded from the study.
Approvals for this study were obtained from the
Medical Research Ethics Committee of the Ministry
of Health Malaysia (NMRR11-456-9126) and Institu-
tional Review Board.
Data collection
Patient demographics were captured using a standard
questionnaire form. A face-to-face interview was
carried out to obtain demographic data, detailed
smokinghistoryandhealth status.TheCanadiancase-
finding questionnaire20 was used to ascertain the like-
lihood of airflow limitation in all subjects. It contains
fivequestions tocapture informationsuchaspresence
of dyspnoea on exertion, chronic cough, sputum
production, wheeze and recurrent respiratory
infections.20 A score of one was awarded for every ‘yes’
response and a zero score for every ‘no’ response.
Hence, a total score could rangebetween0and5. If the
score is ≥3, it is defined as ‘at risk’ and if it is <3, it is
considered as ‘not at risk’.20
In addition, we also assessed the subjects’ per-
ceived health status as a potential predictor for
airflow limitation by asking ‘How do you rate your
current health status?’; a five-point Likert scale
(1 = very bad, 2 = bad, 3 = neutral, 4 = good, 5 = very
good) was used to rate the subjects’ perception of
their health status. Those who rated their health
status as 4 or 5 were defined as having ‘good health’,
whereas those who rated theirs 1 or 2 were considered
to have ‘bad health’.
Once these questionnaires were completed, all
patients were instructed to perform the forced expira-
tory manoeuvre (for at least 6 s) using the COPd-6
device (Model 4000, Vitalograph, Ennis, Ireland).
Although the handheld spirometry measures FEV1
and forced expiratory volume in 6 s (FEV6), it was
unable to measure forced vital capacity (FVC); never-
theless, FEV6 was taken as surrogate for FVC as
studies have shown that FEV6 in this handheld
spirometry is able to reflect quite accurately the
actual value of measured FVC.17–19 Handheld spirom-
etry test was conducted by two trained nurses. A
measurement was deemed to be satisfactory when a
beep sound was heard, indicating that expiration of
at least 6 s had been achieved. Any attempt that did
not produce a beep sound was rejected as unaccep-
table. At least three acceptable measurements were
recorded for each patient. Any patient with ratio of
FEV1/FEV6 <0.75 was considered to have possible
airflow limitation.14,15
These patients were asked to return for formal
spirometry testing, which included a postbroncho-
dilator test in accordance to the standardized pro-
cedure. The highest values of the FEV1 and FVC were
used in the analysis. Diagnosis of COPD was made
when the postbronchodilator FEV1/FVC is <0.70.21
Height and weight were measured, and body mass
index (BMI) was calculated. Obesity was defined
using the Asian cut-off of ≥27.5 kg/m2.22
Statistical analysis
SPSS statistical software version 21 (SPSS IBM,
Armonk, New York, USA) was used for analysis. Con-
tinuous data were described as mean and standard
deviation if the distribution is normal, and when it is
not, median and interquartile range (IQR; 25–75th
percentiles) were also used. Categorical data were
reported as proportions (percentage). Chi-square test
or Fisher’s exact tests were used for the categories or
dichotomous predictors while multivariate logistic
regression analysis was used to search for predictors
of patient with airflow limitation. All variables with a
P-value of less than 0.25 in the univariate analyses
and clinical significant variables were entered into the
multiple logistic regression analysis. All analyses were
performed with 95% confidence intervals (CI), and
the level of significance was set at P < 0.05.
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RESULTS
A total of 437 subjects were enrolled in the study, and
all underwent COPd-6 measurement. Twenty-one
patients had self-reported asthma and were excluded
from our analysis. This gave a total of 416 patients
qualified for final analysis. Of this number, 99.8% of
the respondents weremale, and their median age was
53 years (IQR = 15). The majority (78.8%) were of
Malay extraction. Demographic and clinical charac-
teristics of all patients are presented in Table 1. There
were seven patients with a past history of tuberculo-
sis, but none with lung cancer, occupational lung
disease or bronchiectasis.
The median smoking history was 20.4 (IQR = 18)
pack-years with 63.7% of them still actively smoking.
Average BMI was 27.2 (IQR = 5.8) kg/m2.
Comorbidities were present in 236 (56.7%) individ-
uals. Hypertension (46.2%) and dyslipidaemia
(42.8%) were the two most common comorbidities.
Other comorbidities and general health status were
shown in Table 2.
Prevalence of airflow limitation was 10.6% (n = 44/
416) and 6% (n = 15/251) based on the COPd-6 and
spirometry test, respectively. Of the 44 patients who
had abnormal COPd-6 reading, only 27 came back for
a confirmatory test, with 29.6% (8/27) having spirom-
etry confirmed COPD. On the other hand, among the
224 patients who were screened negative for COPD
with COPd-6, only 3.1 % (7/224) emerged with a diag-
nosis of COPD after spirometry.
More than half (53.4%) of the 416 chronic smokers
in this study were symptomatic. The common com-
plaints were chronic cough particularly in the
morning (32.0%), productive cough (25.5%), dysp-
noea on exertion (20.2%), wheezing (13.5%) and
recurrent respiratory infections (7.5%). Using the
Canadian case-finding questionnaire scoring system,
11.8% were at risk of having airflow limitation.
Over half of the chronic smokers (54.6%) perceived
their health status as ‘good’, 33.6% as ‘neutral’ and
10.8% as ‘bad’. And among the 44 subjects with airflow
limitation, 38.6% subjects reported good health and
18.2% subjects reported bad health.
Table 3 shows the result of multiple logistic regres-
sion. After adjusting for all the variables in the model,
older patients were 3.7 odds more likely to have
airflow limitation (odds ratio (OR) 3.732, 95% CI:
1.100–1.280). Patients with ‘bad health’ were 2.5 odds
more likely to have airflow limitation than those with
‘good health’ (OR = 2.524 95% CI: 1.037–6.142).
Patient who were under or normal weights were 2.9
odds (OR = 2.914 95% CI: 1.191–7.130) more likely to
have airflow limitation compared to the obese
patients.
DISCUSSION
In our study, the prevalence of airflow limitation
based on the handheld COPd-6 spirometer was
10.6%. This is the first study that used a handheld
device in Malaysia. However, when airflow limitation
was confirmed with spirometry, the prevalence of
Table 1 Demographic and clinical characteristics and
airflow limitation in the study population (n = 416)
Variables
No
airflow
limitation
(n = 372)
Have
airflow
limitation
(n = 44)
P-
value
Age, years ( median,
IQR)
53 (13) 60 (20) <0.001
BMI, kg/m2 (n, %)
Underweight ≤ 18.5
and normal
weight (BMI of
18.5–22.9)
60 (84.5) 11 (15.5) 0.043
Overweight BMI of
23.0–27.4
129 (86.6) 20 (13.4)
Obese BMI ≥27.5 183 (93.4) 13 (6.6)
Male gender, n (%) 371 (99.7) 44 (100.0) 0.731
Ethnicity, n (%)
Malays 297 (90.5) 31 (9.5) 0.287
Chinese 29 (80.6) 7 (19.4)
Indians 44 (88.0) 6 (120)
Education level, n (%)
Primary 81 (21.8) 16 (36.4) 0.080
Secondary 223 (59.9) 23 (52.3)
Tertiary 68 (18.3) 5 (11.4)
Smoking history,
pack-years, n (%)
<20 171 (46.0) 13 (29.5) 0.038
≥20 201 (54.0) 31 (70.5)
Salary, RM (median,
IQR)
1500 (2200) 1500 (1773) 0.213
Approximate
USD (median, IQR)
450 (660) 450 (530) -
Data are presented as median (IQR) or n (%).
BMI, body mass index; IQR, interquartile range; n, number;
RM, ringgit Malaysia; USD, United States dollar.
Table 2 Patient characteristics (n = 416)
Variables
No
airflow
limitation
Have
airflow
limitation P-value
Canadian case-finding scoring
Not at risk with the score
<3, n (%)
328 (88.2) 39 (88.6) 0.928
At risk with score ≥3, n (%) 44 (11.8) 5 (11.4)
Patients’ perception on their general well-being
Bad, n (%) 37 (9.9) 8 (18.2) 0.096
Not in bad condition, n (%) 335 (90.1) 36 (81.8)
Comorbidities
Hypertension, n (%) 168 (45.2) 24 (54.5) 0.238
Dyslipidaemia, n (%) 159 (42.7) 19 (43.2) 0.956
Cardiovascular heart
disease, n (%)
12 (3.2) 1 (2.3) 0.731
Heart failure, n (%) 22 (5.9) 3 (6.8) 0.811
Data are presented as n and %.
n, number.
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COPD was 6.0%. This suggests that handheld spirom-
etry tends to overestimate the prevalence of COPD.
On the other hand, overestimation could be due to
the higher cut-off point for FEV1/FEV6 (less than 0.75)
based on the handheld spirometry compared with
FEV1/FVC (less than 0.70) using spirometry, the gold
standard test to determine airflow limitation. Among
those screened positive with COPd-6, about one third
were confirmed to have COPD. One possible reason
could be due to the failure of almost 40% of those
screened as having COPD by COPd-6 to have a con-
firmatory test.
The prevalence of airflow limitation in our study is
higher compared with the reported estimated preva-
lence of COPD of 4.7% in Malaysia.22 However, the
reported prevalence is not based on direct spirometry
measurements, but on theoretical modelling of
smoking rates and levels of air pollution in Malaysia
10 years ago.22 In addition, the estimation was calcu-
lated for patients with at least moderately severe
COPD.When compared with other studies performed
in Asia, this prevalence of COPD (6%) is lower com-
pared with the spirometry-based prevalence reported
by other countries, which varied from 6.5% in India,
7.50% in Korea and 8.55% in Japan.23–25 Extensive use
of biomass fuel relating to indoor cooking, which is
uncommon in Malaysia, particularly in this non-
remote area of this population, may contribute to
these differences.
This study demonstrated that poorer health status
is a predictor for the presence of airflow limitation
(OR = 2.524 95%CI: 1.037–6.142). Self-reported health
status outcomes are often relevant in patients with
COPD as they reflect the well-being of patients with
COPD attributed to the relatively asymptomatic early
stage of this disease.26 The Canadian case-finding
questionnaire scoring systemwas not helpful to iden-
tify patients at risk of airflow limitation. There could
be a possible cultural influence to this finding. Studies
have reported that the majority of patients in Asia
who had COPD did not report symptoms of cough,
sputum production and breathlessness—three symp-
toms that were included in the Canadian case-finding
questionnaires.27–29 Further research is needed to vali-
date the usefulness of these questionnaires in Asian.
In this study, almost all the respondents were
males. Tobacco smoking among women is regarded
as a socially unaccepted behaviour in Malaysia.30
Therefore, fewer females in the country smoke,
thus contributing to the low prevalence of airflow
limitation compared with Nepal and other western
countries.31,32
The chief limitation of this study is that more than
60% of the patients with a positive diagnosis of COPD
with the handheld device did not come back for the
confirmatory standard spirometry testing. However,
under the circumstances of a limited budget and
resources in the primary care setting, together with
the previous report of good sensitivity and specificity
of the handheld spirometer, we consider that using
the handheld device would be appropriate in these
settings. The diagnosis of asthma and bronchiectasis
were based on self-report; thus, this could have
caused over or under estimation of COPD prevalence.
In conclusion, this study found that using the hand-
held spirometer (COPd-6), the prevalence of airflow
limitation was estimated as ∼10%. Risk factors for
airflow limitation were identified.
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